Evidence map›Paper›PMID 27216734›Full record

ArticleMalaria journal2016

The epidemiology of residual Plasmodium falciparum malaria transmission and infection burden in an African city with high coverage of multiple vector control measures.

Daniel Msellemu, Hagai I Namango, Victoria M Mwakalinga, Alex J Ntamatungiro, Yeromin Mlacha, Zacharia J Mtema, Samson Kiware, Neil F Lobo, Silas Majambere, Stefan Dongus and 4 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Larviciding to prevent malaria transmission.The Cochrane database of systematic reviews · 2019
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Laboratory and semi-field evaluation of the efficacy ofCurrent research in parasitology & vector-borne diseases · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 6 countries.

Daniel MsellemuEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Hagai I NamangoEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Victoria M MwakalingaEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Alex J NtamatungiroEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Yeromin MlachaEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Zacharia J MtemaEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Samson KiwareEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Neil F LoboEck Institute for Global Health, Notre Dame University, Notre Dame, IN, USA.
Silas MajambereEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Stefan DongusEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Christopher J DrakeleyDepartment of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK.
Nicodem J GovellaEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Prosper P ChakiEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
Gerry F KilleenEnvironmental Health and Ecological Sciences Thematic Group, Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania. gkilleen@ihi.or.tz.
Ifakara Health Institute · TZLiverpool School of Tropical Medicine · GBLondon School of Hygiene & Tropical Medicine · GBUniversity of Basel · CHUniversity of Notre Dame · USUniversity of the Witwatersrand · ZA

Funding

Wellcome TrustWellcome Trust 087547/Z/08/Z
6 · The paper itself

Abstract

backgroundIn the Tanzanian city of Dar es Salaam, high coverage of long-lasting insecticidal nets (LLINs), larvicide application (LA) and mosquito-proofed housing, was complemented with improved access to artemisinin-based combination therapy and rapid diagnostic tests by the end of 2012.

methodsThree rounds of city-wide, cluster-sampled cross-sectional surveys of malaria parasite infection status, spanning 2010 to 2012, were complemented by two series of high-resolution, longitudinal surveys of vector density.

resultsLarvicide application using a granule formulation of Bacillus thuringiensis var. israelensis (Bti) had no effect upon either vector density (P = 0.820) or infection prevalence (P = 0.325) when managed by a private-sector contractor. Infection prevalence rebounded back to 13.8 % in 2010, compared with <2 % at the end of a previous Bti LA evaluation in 2008. Following transition to management by the Ministry of Health and Social Welfare (MoHSW), LA consistently reduced vector densities, first using the same Bti granule in early 2011 [odds ratio (OR) (95 % confidence interval (CI)) = 0.31 (0.14, 0.71), P = 0.0053] and then a pre-diluted aqueous suspension formulation from mid 2011 onwards [OR (95 % CI) = 0.15 (0.07, 0.30), P ≪ 0.000001]. While LA by MoHSW with the granule formulation was associated with reduced infection prevalence [OR (95 % CI) = 0.26 (0.12, 0.56), P = 0.00040], subsequent liquid suspension use, following a mass distribution to achieve universal coverage of LLINs that reduced vector density [OR (95 % CI) = 0.72 (0.51, 1.01), P = 0.057] and prevalence [OR (95 % CI) = 0.80 (0.69, 0.91), P = 0.0013], was not associated with further prevalence reduction (P = 0.836). Sleeping inside houses with complete window screens only reduced infection risk [OR (95 % CI) = 0.71 (0.62, 0.82), P = 0.0000036] if the evenings and mornings were also spent indoors. Furthermore, infection risk was only associated with local vector density [OR (95 % CI) = 6.99 (1.12, 43.7) at one vector mosquito per trap per night, P = 0.037] among the minority (14 %) of households lacking screening. Despite attenuation of malaria transmission and immunity, 88 % of infected residents experienced no recent fever, only 0.4 % of these afebrile cases had been treated for malaria, and prevalence remained high (9.9 %) at the end of the study.

conclusionsWhile existing vector control interventions have dramatically attenuated malaria transmission in Dar es Salaam, further scale-up and additional measures to protect against mosquito bites outdoors are desirable. Accelerated elimination of chronic human infections persisting at high prevalence will require active, population-wide campaigns with curative drugs.

Indexed as

AdolescentAdultAfricaAgedAged, 80 and overAnimalsChildChild, PreschoolCross-Sectional StudiesDisease Transmission, InfectiousFemaleHumansInfantInfant, NewbornLongitudinal StudiesMalaria, FalciparumAnophelesChronic infectionHousingLarval source managementLong-lasting insecticidal netMalariaMosquitoPlasmodiumVector controlWindow screening

Identifiers

PMID27216734
PMCPMC4877954
OpenAlexW2396475549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.